Australia to continue AstraZeneca vaccination despite blood clotting case | Inquirer News

Australia to continue AstraZeneca vaccination despite blood clotting case

/ 02:10 PM April 04, 2021

A medical worker prepares a dose of Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp, Belgium March 18, 2021

FILE PHOTO: A medical worker prepares a dose of Oxford/AstraZeneca’s COVID-19 vaccine at a vaccination center in Antwerp, Belgium March 18, 2021. REUTERS/Yves Herman/File Photo

MELBOURNE — Australia will continue its inoculation program with AstraZeneca PLC, health officials said on Saturday, after a blood clotting case raised concern about the safety of the vaccine.

A 44-year-old man was admitted to a Melbourne hospital with clotting, days after receiving the AstraZeneca vaccine, suffering serious thrombosis, a condition that prevents normal blood flow though the circulatory system.

Article continues after this advertisement

The Therapeutic Goods Administration (TGA) regulator and a panel, the Australian Technical Advisory Group on Immunization (ATAGI), met late Friday and early Saturday to discuss further advice on the AstraZeneca vaccine.

FEATURED STORIES

“We have not been advised at this time by ATAGI or the TGA to pause the rollout of the AstraZeneca vaccine in Australia,” Australia’s deputy chief medical officer, Michael Kidd, told a televised briefing Saturday afternoon.

Kidd said, however, that the blood clotting case is “likely” related to the vaccine.

Article continues after this advertisement

“The risks of serious side effects remain very low, but safety is paramount and that is why TAGI and the TGA are continuing to do due diligence on this case,” Kidd said, adding that further announcements would come next week.

Article continues after this advertisement

On Thursday, Britain identified 30 cases of rare blood clot events following use of the vaccine. Several nations, including Canada, France, Germany and Spain, limited its use after similar reports.

Article continues after this advertisement

Possible complications with the rollout of the AstraZeneca vaccine could further slow the already delayed inoculation drive in Australia.

Australia launched mass vaccinations for its 25 million people in February, with most expected to receive the University of Oxford/AstraZeneca vaccine, as 50 million doses are being produced domestically by CSL Ltd.

Article continues after this advertisement

The country has had troubles, however, rolling out the program, missing a March target by about 3.3 million doses as states and the federal government bickered over the blame.

The troubles follow a year of significant success curbing the virus, with snap lockdowns, border closures and swift tracking limiting coronavirus infections to just under 29,300 infections, with 909 COVID-19 deaths.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

On Saturday, Queensland state, the epicenter of the most recent small outbreak of the coronavirus, recorded one new infection, health officials said, but risks to the public were minimal as the victim had been in isolation for days.

TAGS: AstraZeneca, Australia, thrombosis

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.